An observational study in Asthma, sponsored by Queen's University, Belfast. Enrolling by invitation at 1 site in United Kingdom. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.
Sponsored by Queen's University, Belfast · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 558 studies in Asthma with a site in United Kingdom — 52 open to participants now, 71 under way, 11 of them phase 3. Asthma · United Kingdom.
Among the 558 studies in Asthma with a site in United Kingdom, this one is the 15th largest by planned enrollment of the 131 observational ones that give a count, is one of 15 that started in 2020, is one of 131 observational ones, reaches primary completion later than 65 of the 70 other live ones, and was the 418th registered.
4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.
Browse Asthma studies →52 of the 558 studies in Asthma with a site in United Kingdom are open now. Recruiting first, the newest first:
Richmond Research Institute · Sites in United Kingdom
Ages 18+
Chiesi Farmaceutici S.p.A. · Sites in United Kingdom
Ages 18–65 · Healthy volunteers
Liverpool Heart and Chest Hospital NHS Foundation Trust · Sites in United Kingdom
Ages 18–110
GlaxoSmithKline · Sites in United Kingdom, United States, Argentina and 1 more country
Ages 18+
University of Leeds · Sites in United Kingdom
Ages 18–70
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.
This study: 16 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
558 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 87 · Phase 2 132 · Phase 3 83 · Phase 4 50
First in 1991; this study’s year is marked. 15 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 4,800 is above the median of 159 across 1,254 observational studies indexed under Asthma.
Median enrollment 69 across the 427 interventional studies, 149 across the 131 observational. Of the 445 that completed or were terminated, 155 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
320 of 558 have an industry lead sponsor. The 10 most frequent:
Queen's University, Belfast is the lead sponsor of 117 studies on the registry; 14 are open to participants now.
Queen's University, Belfast has 6 studies filed under Asthma — fewer than ten, so there is no comparison to draw.
23 of the studies in Asthma with a site in United Kingdom that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05692180Phase 3AstraZenecaA Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma | 2026-12-23 |
| NCT07645248Phase 3GlaxoSmithKlineA Study to Compare Safety of 4 Weeks Exposure to Propellants Hydrofluoroalkane 1,1-difluoroethane (HFA-152a) and HFA-1,1,1,2-tetrafluoroethane (134a) | 2026-12-28 |
| NCT06473779Phase 3AstraZenecaOpen-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma. | 2027-06-25 |
| NCT07833826University of NottinghamN-WATCH: Nottingham Wheeze Assessment in Tidal Children | 2026-12-31 |
| NCT07488897RIGImmune Inc.RIG 101 Trial in Healthy Adults and Adults With Asthma | 2027-02 |
Add all 23 to your calendar (.ics) → With an account.
Among the 558 studies in Asthma with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A "Clinical Registry" is a database which contains clinical information about people with different medical conditions. They are used in many countries throughout the world to help medical teams to better understand specific diseases and improve the care and treatment of patients.
The UK Severe Asthma Registry has been collecting data on patients attending Severe Asthma Clinics in the UK since 2007.
After obtaining appropriate consent from patients to use their information, data is entered by the patient's own clinical team and it is kept up-to-date to follow clinical progress and response to treatments. Very strict controls are in place to make sure individuals cannot be identified from the Registry and all information available from the National Registry is anonymous.
Apart from the local clinic team, occasionally trusted third parties will also be able to identify you, if required to do so, on a strict need-to-know basis. This is necessary to ensure that the Registry works efficiently, or as a part of a Research Project, previously approved by a Research Ethics Committee.
Data from the Registry has a number of uses including judging which severe asthma treatments are of greater benefit, to identify different subgroups of severe asthma and trial new therapies and to provide information for planning future services for people with severe asthma. The use of any information from the UK Severe Asthma Registry requires approval of the Steering Committee which is made up of the refractory asthma specialists from across the UK and who will have access to data protection, legal and ethics expertise where necessary, to safeguard the use of data.
If the Registry closes, data will be returned to the local clinic team if requested, otherwise it will be destroyed. Participation is entirely voluntary and patients can withdraw consent form the Registry at any time by informing their local clinical team. The Data Controller from the UK Severe Asthma Registry is Queen's University Belfast and the Data Processor is Dendrite Clinical Services Ltd which is a commercial provider of database and registry systems.
There are currently 14 Networks of UK dedicated Specialist Difficult Asthma Services submitting data to the UK Registry: Belfast City Hospital; Royal Brompton \& Harefield, London; Birmingham Regional Severe Asthma Service; South Thames \& Kent Severe Asthma Service; East Midlands Severe Asthma Network; North West Midlands Severe Asthma Service; Yorkshire Asthma MDT; East of England Severe Asthma Network; Wessex Severe Asthma Network; South West Asthma Network; North West Asthma Network, Newcastle Severe Asthma Network and Greater Glasgow \& Clyde.
The Registry was set up to standardise clinical services in the UK and facilitate research into patients with difficult asthma. Patients that attend difficult asthma services across the UK are approached to give consent for inclusion. The Registry is hosted online by Dendrite Clinical Systems and admits password protected anonymised data, after fully informed written consent is obtained from patients (see Patient Information and Consent sheets). The individual centre data can be downloaded locally by registered users for audit purposes. The Registry records patient demographics including gender, age at diagnosis, race, occupation, smoking status, BMI. Disease characteristics such as asthma medication, unscheduled healthcare visits, exacerbations, hospital and ICU admissions, blood and sputum investigations, allergen testing, pulmonary function are also recorded in the registry.
Subjects have been entered into the Registry in a non-selected manner and there are currently over 4800 subjects in the Registry with detailed demographic, disease characteristics and health outcome data. Of these subjects, the majority after detailed assessment fulfil the American Thoracic Society definition of refractory asthma, whilst others after detailed assessment are identified as having non-refractory asthma.
The Registry has also been expanded to collect data on bronchial thermoplasty in line with NICE Guidance on bronchial thermoplasty for severe asthma (http://www.nice.org.uk/guidance/ipg419).
the Registry with detailed demographic, disease characteristics and health outcome data.
As part of NHS England Central Commissioning for Specialist Severe Asthma Services, all specialist centres in the UK will be required to input data into the Registry to enable benchmarking between centres.
Patients that are referred to specialist severe asthma services across the UK. The majority of patients after detailed assessment fulfill the American Thoracic Society definition of refractory asthma, whilst others after detailed assessment are identified as having non-refractory asthma.
Inclusion Criteria:
1. Referral to a specialist severe asthma clinic in the UK due to inadequate asthma control
Exclusion Criteria: None
Proportion of patients with no systemic corticosteroid exposure in most recent 12 month follow-up period
Time frame: 5 years
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2020 (actual). Primary completion is estimated for Aug 2030, 120 months after the start.
Of 366 non-industry observational studies under Asthma, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 97. This study's planned 120 months is above that.
Counting every sponsor, half of 456 studies reached it within 36 months; a quarter within 18 and three quarters within 82.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 7, 2026: primary completion Aug 2025 → Aug 2030 and completion Aug 2025 → Aug 2030.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.